Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since May 25 · above the Ichimoku cloud · RSI 79 (overbought) · MACD above its signal · 1% below its 52-week high
None of the 29 investors followed here reported a position in FPH.NZ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FPH.NZ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for FPH.NZ.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.1 | 5.1 | -8.6 | -2.2 | 2.0 | 4.6 | 4.3 | 9.1 | 3.6 | 5.9 | +29.0% | ||
| 2025 | -2.1 | -9.4 | -1.6 | 1.4 | 7.4 | -1.2 | 2.1 | -0.5 | 1.2 | 0.1 | 0.5 | 1.2 | −1.7% |
| 2024 | 0.3 | 3.5 | 4.7 | 11.0 | 3.6 | 2.0 | 7.5 | 10.0 | -2.4 | 3.6 | 5.7 | 0.9 | +62.7% |
| 2023 | 11.8 | 2.9 | 2.6 | 3.9 | -16.0 | 5.4 | 0.3 | -7.6 | -5.0 | -3.6 | 13.2 | 0.2 | +4.4% |
| 2022 | -15.3 | -0.9 | -11.5 | -11.7 | -2.3 | -4.9 | 6.1 | -7.3 | -5.9 | 5.8 | 20.5 | -4.2 | −31.0% |
| 2021 | 5.1 | -15.6 | 9.7 | 12.0 | -17.1 | 4.5 | 1.4 | 4.9 | -3.3 | -2.5 | 6.8 | -1.7 | −0.6% |
| 2020 | 5.0 | 10.6 | 17.8 | -9.8 | 9.5 | 18.7 | 1.1 | 2.4 | -9.7 | 5.2 | 2.6 | -8.2 | +48.5% |
| 2019 | -3.4 | 17.0 | 6.8 | 0.7 | -2.6 | 0.4 | 6.7 | 0.9 | 3.9 | 10.7 | 15.7 | 0.2 | +70.8% |
| 2018 | -7.0 | 3.4 | -4.3 | -3.4 | 4.2 | 12.1 | -0.6 | 10.7 | -8.2 | -9.6 | -2.2 | -2.3 | −9.4% |
| 2017 | 2.0 | 4.8 | 6.5 | 3.8 | 6.3 | 7.1 | -4.3 | 7.3 | 8.6 | 3.7 | -1.1 | 9.5 | +68.4% |
| 2016 | -2.8 | 1.7 | 11.4 | -6.6 | 14.2 | -3.8 | 4.5 | -7.9 | 3.5 | -11.5 | -7.7 | 4.2 | −4.3% |
| 2015 | -0.6 | 10.3 | -3.9 | -1.2 | 1.5 | 3.8 | 9.5 | -3.3 | -2.1 | 9.6 | 8.1 | 5.8 | +42.4% |
| 2014 | 5.2 | -1.0 | 6.0 | -3.8 | 12.5 | 3.3 | 0.0 | 7.8 | 1.4 | 7.7 | -2.0 | 14.1 | +62.3% |
| 2013 | -3.6 | 8.0 | 1.9 | 1.1 | 17.7 | 10.6 | 0.9 | 2.3 | 1.7 | 1.7 | 2.4 | 2.1 | +55.9% |
| 2012 | -15.5 | 0.5 | 4.7 | -0.9 | -7.7 | -3.9 | -3.0 | 12.6 | 7.0 | 2.2 | 8.9 | -3.5 | −2.0% |
| 2011 | 2.3 | -4.7 | 3.6 | -1.6 | -6.8 | -4.2 | -9.4 | -10.8 | 13.5 | -8.3 | 3.4 | 5.0 | −19.0% |
| 2010 | 0.6 | 0.3 | -3.5 | 7.6 | -8.2 | -3.7 | -3.2 | -3.3 | 1.7 | 9.1 | -8.0 | 4.4 | −7.7% |
| 2009 | 7.3 | -1.2 | -5.4 | -3.8 | -4.6 | 0.7 | 11.3 | 0.0 | 0.9 | -5.5 | 2.6 | 6.0 | +7.0% |
| 2008 | -13.2 | -12.9 | 11.0 | -8.9 | -10.1 | -2.1 | 19.1 | 12.5 | -7.0 | 1.4 | 3.4 | 2.6 | −9.7% |
| 2007 | -0.5 | -8.0 | -6.9 | 2.8 | -5.1 | -4.8 | 0.3 | 0.0 | -2.4 | -1.5 | -3.1 | 10.8 | −18.1% |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Buy / hold / sell counts
No recent headlines.